A broadly neutralizing human monoclonal antibody against the hemagglutinin of avian influenza virus H7N9.

ABSTRACT:

Background

The new emerging avian influenza A H7N9 virus, causing severe human infection with a mortality rate of around 41%. This study aims to provide a novel treatment option for the prevention and control of H7N9.

Methods

H7 hemagglutinin (HA)-specific B cells were isolated from peripheral blood plasma cells of the patients previously infected by H7N9 in Jiangsu Province, China. The human monoclonal antibodies (mAbs) were generated by amplification and cloning of these HA-specific B cells. First, all human mAbs were screened for binding activity by enzyme-linked immunosorbent assay. Then, those mAbs, exhibiting potent affinity to recognize H7 HAs were further evaluated by hemagglutination-inhibiting (HAI) and microneutralization in vitro assays. Finally, the lead mAb can

SUBMITTER: Li J 

PROVIDER: S-EPMC9276153 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature